 Biocept Inc told investors that its cerebrospinal fluid assay CNSide had been shown to be able to detect markers of a complication of non-small cell lung cancer NSCLC, which could mean targeted treatment that would allow patients lives to be extended. More than 198,000 people are diagnosed with NSCLC each year, said Biocept, and an estimated 3-9 of those will develop leptomeningeal carcinomatosis LMC, where the cancer spreads to the membranes surrounding the brain and spinal cord. 